ScholarLens Back to search
2016•The Lancet OncologyOpen access

Carfilozomib versus bortezomib for relapsed or refractory myeloma

Steven E. Vogl

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Carfilzomib, Medicine, Bortezomib, Dexamethasone, Discontinuation, Multiple myeloma, Refractory (planetary science), Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Carfilozomib versus bortezomib for relapsed or refractory myeloma — Research Paper | ScholarLens